reports
Pennant Announces First Quarter 2025 Earnings Release and Call
Pennant Announces First Quarter 2025 Earnings Release and Call EAGLE, Idaho, April 21, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of operating subsidiaries that provide home health, hospice and senior living services, announced today that it expects to issue its first quarter 2025 financial results on Tuesday, May 6, 2025. Pennant invites current and prospective investors to tune into a live webcast to be held the following day, Wednesday, May 7, 2025, at 10:00 a.m. Mountain Time (12:00 p.m. Eastern Time), during which Pennant’s management will di...
Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-Worl...
Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency - Data from the largest retrospective analysis of ENPP1 Deficiency provides insights into the evolution of the disease’s serious cardiovascular and musculoskeletal complications - - Findings highlight the urgent need for early and improved diagnosis, care and treatments that address the long-term systemic effects of ENPP1 Deficiency - BOSTON, April 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative the...
- Wedbush Research
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FB FACEBOOK INC. CLASS A
BPMC BLUEPRINT MEDICINES CORP.
7974 NINTENDO CO. LTD.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
WVE WAVE LIFE SCIENCES
PTGX PROTAGONIST THERAPEUTICS
ARGX ARGENX ADS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
GM GENERAL MOTORS COMPANY
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
PINS PINTEREST INC. CLASS A
SWTX SPRINGWORKS THERAPEUTICS
SMCI SUPER MICRO COMPUTER
RVMD INC.
INZY REVOLUTION MEDICINES
TVTX INOZYME PHARMA
VRDN TRAVERE THERAPEUTICS INC
NUVB VIRIDIAN THERAPEUTICS INC
DAWN NUVATION BIO INC (A)
STX DAY ONE BIOPHARMACEUTICALS INC
GFS SEAGATE TECHNOLOGY HLDGS PLC
GMTX GLOBALFOUNDRIES INC
JANX GEMINI THERAPEUTICS INC
MLTX JANUX THERAPEUTICS INC
NUVL MOONLAKE IMMUNOTHERAPEUTICS
APGE NUVALENT INC
ORKA APOGEE THERAPEUTICS INC
ORUKA THERAPEUTICS INC
- David Nierengarten
- Dennis Pak
- Dylan Shindler
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Yun Zhong
BPMC BLUEPRINT MEDICINES CORP.
PTGX PROTAGONIST THERAPEUTICS
ARGX ARGENX ADS
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
SWTX SPRINGWORKS THERAPEUTICS
RVMD REVOLUTION MEDICINES
INZY INOZYME PHARMA
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
NUVB NUVATION BIO INC (A)
DAWN DAY ONE BIOPHARMACEUTICALS INC
GMTX GEMINI THERAPEUTICS INC
JANX JANUX THERAPEUTICS INC
MLTX MOONLAKE IMMUNOTHERAPEUTICS
NUVL NUVALENT INC
APGE APOGEE THERAPEUTICS INC
Pennant Expands Portfolio with Acquisition of Senior Living Community ...
Pennant Expands Portfolio with Acquisition of Senior Living Community in Arizona EAGLE, Idaho, April 01, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, announces the acquisition of the real estate and operations of an established senior living community in Arizona. The newly acquired community offers assisted living and memory care services, and increases Pennant’s Arizona operations by 128 units. “This acquisition aligns with our mission to provide lif...
Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healt...
Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Doug Treco, Ph.D., CEO and Chairman of Inozyme, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, from 2:15-2:55pm ET. A live webcast of the fireside chat can be...
- Jonathan Moreland
PSEC PROSPECT CAPITAL CORPORATION
MG MISTRAS GROUP
LPSN LIVEPERSON INC.
GCO GENESCO INC.
QRHC QUEST RESOURCE HOLDING
CULP CULP INC.
CMCO COLUMBUS MCKINNON CORPORATION
GCBC GREENE COUNTY BANCORP INC.
FLWS 1-800-FLOWERS.COM CL A
GRWG GROWGENERATION
BDTX BLACK DIAMOND THERAPEUTICS
ENX INC.
ECAT EATON VANCE NEW YORK MUNICIPAL BOND FUND
BUKS BLACKROCK ESG CAP ALLOCATION TR
SBGI BUTLER NATIONAL CORP
SRBK SINCLAIR INC
ADVM SR BANCORP INC
SUNS ADVERUM BIOTECHNOLOGIES INC.
SUNRISE REALTY TRUST
atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial...
atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights - Dosed the first patient in the Phase 2 Elumina trial of VLS-01 (buccal film DMT) for patients with treatment-resistant depression; topline data anticipated in Q1’26 - Initiated a Phase 2 clinical trial of EMP-01 (oral R-MDMA) for patients with social anxiety disorder; topline data anticipated in Q1’26 - Beckley Psytech completed enrollment in the Phase 2b study of BPL-003 (intranasal mebufotenin benzoate) in patients with treatment-resistant depression; topline data anticipate...
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase...
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression - Elumina is a Phase 2, multicenter, double-blind, randomized, placebo-controlled, clinical trial to assess the efficacy, safety and tolerability of VLS-01 (buccal film DMT) in people suffering from treatment-resistant depression - VLS-01 is being developed as a rapid-acting, robust and durable antidepressant for people suffering from treatment-resistant depression, which affects approximately 100 million people globally - VLS-01 is designed to fit ...
Inozyme Pharma Reports Full Year 2024 Financial Results and Announces ...
Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights - Cash, cash equivalents and short-term investments as of December 31, 2024, and anticipated cost savings from prioritizing ENPP1 Deficiency program, including an approximately 25% workforce reduction, expected to support operations into the first quarter of 2026 - - Enrollment complete in ENERGY 3 pivotal trial in pediatric patients with ENPP1 Deficiency; topline data expected in first quarter of 2026 - - Positive interim result...
- David Nierengarten
- Dennis Pak
- Martin Fan
Pennant Group to Participate in the 2025 Oppenheimer Annual Healthcare...
Pennant Group to Participate in the 2025 Oppenheimer Annual Healthcare Conference EAGLE, Idaho, March 07, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, announced today that it will participate in the upcoming 2025 Oppenheimer Co. Annual Healthcare MedTech & Services Conference on March 18, 2025. Brent Guerisoli, Chief Executive Officer, Lynette Walbom, Chief Financial Officer, and Kirk Cheney, Executive Vice President, will participate in a fireside chat on March 18,...
atai Life Sciences Announces Completion of Enrollment in Phase 2b Clin...
atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression - The eight-week, quadruple-masked, dose-finding, core stage of the Phase 2b clinical trial is evaluating the efficacy and safety of a single dose of BPL-003 (mebufotenin benzoate) in patients with treatment-resistant depression - The open-label extension stage of the Phase 2b clinical trial continues to enroll patients to evaluate the safety and efficacy of a second dose of BPL-003 - As previously reported, the Phase 2a study of BPL-003 in patients with ...
Pennant Reports Fourth Quarter and Fiscal Year 2024 Results
Pennant Reports Fourth Quarter and Fiscal Year 2024 Results Conference Call and Webcast scheduled for tomorrow, February 28, 2025 at 10:00 am MT EAGLE, Idaho, Feb. 27, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, today announced its operating results for the fiscal year and fourth quarter of 2024, reporting GAAP diluted earnings per share of $0.70 and $0.16 for the year ended December 31, 2024 and the fourth quarter, respectively. Pennant also reported adjusted di...
atai Life Sciences to Participate in the TD Cowen 45th Annual Health C...
atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference NEW YORK and BERLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team is scheduled to participate in the TD Cowen 45th Annual Health Care Conference in Boston, MA from March 3-5, 2025. Details of the company’s participation: Format: Fireside chat and 1x1 investor meetingsDate and Time: Fireside chat on Monday, March 3 at 11:50 ...
Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conf...
Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Doug Treco, Ph.D., CEO and Chairman of Inozyme, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, from 1:10-1:40pm ET. A live webcast of the presentation can be accessed from the Investor Relations sec...
- Jonathan Moreland
WYNN WYNN RESORTS LIMITED
TTSH TILE SHOP HOLDINGS INC.
OXBR OXBRIDGE RE HOLDINGS
NGL NGL ENERGY PARTNERS LP
HMC HARMONIC
HII HUNTINGTON INGALLS INDUSTRIES INC.
EL ESTEE LAUDER COMPANIES INC. CLASS A
CVS CVS HEALTH CORPORATION
CPSI COMPUTER PROGRAMS & SYSTEMS INC.
BZH BEAZER HOMES USA INC.
BMY BRISTOL-MYERS SQUIBB COMPANY
ASYS AMTECH SYSTEMS INC.
ARCC ARES CAPITAL CORPORATION
AIG AMERICAN INTERNATIONAL GROUP INC.
MDU MDU RESOURCES GROUP INC
CMCO COLUMBUS MCKINNON CORPORATION
USFD US FOODS HOLDING CORP.
FRD FRIEDMAN INDUSTRIES INC.
PLBC PLUMAS BANCORP
FBK FB FINANCIAL CORPORATION
MRUS MERUS B V
PFE PFIZER INC.
XFLT XAI OCTAGON FLOATING RATE ALTERNATIVE INCOME TERM TRUST
RCUS ARCUS BIOSCIENCES
NWPP NEW PEOPLES BANKSHARES INC.
EAF GRAFTECH INTERNATIONAL
AMCR AMCOR PLC
BFC BANK FIRST NATIONAL CORP
CBKM CONSUMERS BANCORP INC.
IDYA IDEAYA BIOSCIENCES
RZLT REZOLUTE
REYN INC.
MTCH REYNOLDS CONSUMER PRODUCTS INC.
ESOA MATCH GROUP INC.
ATAI ENERGY SERVICES OF AMERICA CORP.
FLNC ATAI LIFE SCIENCES BV
BST FLUENCE ENERGY INC
PCT BLACKROCK SCIENCE AND TECHNOLOGY TRUST
CMPO PURECYCLE TECHNOLOGIES INC
EFSI COMPOSECURE INC
LSMG EAGLE FINANCIAL SERVICES INC
SLDB LODE STAR MINING INC
RCEL SOLID BIOSCIENCES INC
MNR AVITA MEDICAL INC
OCX MACH NATURAL RESOURCES LP
FDBC ONCOCYTE CORPORATION
FIDELITY D & D BANCORP INC
Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 ...
Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025 BOSTON, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Kurt Gunter, M.D., Senior Vice President and Chief Medical Officer, will present data from the company’s Expanded Access Program (EAP) evaluating INZ-701 in infants and chi...
atai Life Sciences Announces Closing of Public Offering and Full Exerc...
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares NEW YORK and BERLIN, Feb. 20, 2025 (GLOBE NEWSWIRE) -- e Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced that, on February 14, 2025, the closing of its public offering of 26,190,477 common shares occurred. Additionally, on February 17, 2025, the underwriter exercised its option in full to purchase an additional 3,928,571 common shares at the public...
- Jonathan Moreland
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.